Aedifica, Cofinimmo: Aedifica CMD feedback bpost: 1Q25 results beat strongly, outlook surprises Brunel: 1Q25 results disappoint on perm, weak revenue Cofinimmo, Aedifica: Negative reaction on Aedifica offer Eurocommercial Properties: Good with no surprise Montea: Good results, guidance reconfirmed Proximus: Small 1Q beat, guidance reiterated, soft commercial performance Sif Group: The jury is still out Talabat: Preview 1Q25 Universal Music Group: Peer Warner Music slowdown in streaming and prof...
A director at Cofinimmo sold 2,600 shares at 77.399EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
The ongoing tariff war continues to create uncertainty for investors, with a trade embargo between the US and China. Although Europe has received a temporary reprieve, the prolonged situation could result in significant economic damage. We are maintaining a defensive stance in our Benelux Dynamic Top Pick List, as the Federal Reserve holds steady and the European Central Bank may continue lowering rates. Pessimism regarding the European industry has increased, though some US-based European compa...
GENFIT : Assemblée Générale Mixte du 17 juin 2025 — modalités de mise à disposition des documents préparatoires Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 7 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui la publication dans l’édition du Bulletin des Annonces Légales Obligatoires n° 55 du 7 mai 2025 de son avis de réunion valant convocation à l’Assemblée Générale Mixte qui se déroulera le 17 ju...
GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 7, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the May 7, 2025 French legal announcements bulletin n°55 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on June 17, 2025, at 10:00 am (CET), at...
Ahold Delhaize: Strong 1Q25 in the US, additional details on FY25 guidance. Arcadis: Mixed start to FY25, US not to blame. PostNL: Highlights of 1Q25 analyst meeting. Sif Group: Preview - EBITDA capacity of new factory is key. Vonovia: Good results, positive message about valuations, new CEO. Wolters Kluwer: 1Q25 trading update – good start to the year
GENFIT to Present Latest ACLF Research at EASL Congress 2025 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 5, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces its participation at the European Association for the Study of the Liver (EASL) Annual Congress 2025 with six posters presenting the latest research in ACLF and multiple events highlighting the growing importance of ACLF within the hepatology community. I. Poste...
GENFIT présentera ses dernières avancées dans l'ACLF à l’EASL Congress 2025 Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 5 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui sa participation au Congrès 2025 de l’EASL1 avec six posters présentant notamment les derniers travaux de recherche sur l'ACLF, et plusieurs événements témoignant de l'importance croissante de l'ACLF au sein de la communauté des...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.